• In late July 2026, several law firms announced class action lawsuits against PROCEPT BioRobotics alleging that an undisclosed discount program led customers to buy handpiece units in volumes that materially exceeded procedure demand, inflating reported U.S. sales and creating more than 10,000 excess units of field inventory by the end of 2025.
• The complaints also claim PROCEPT’s guidance for 2025 lacked a reasonable factual basis because management allegedly knew pulled-forward sales and overstocked customers could expose the business to significant operational and financial risks.
• Next, we will examine how allegations around this undisclosed bulk-order discount program may alter PROCEPT BioRobotics’ investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT, you have to believe Aquablation and the HYDROS platform can keep gaining share in urologic surgery while recurring handpiece revenue supports a path toward better margins. The recent class actions and allegations about undisclosed discounting directly touch that consumables engine and make inventory quality and demand visibility the key near term catalyst, while also elevating execution and credibility as the most immediate risk to the story.

The February 25, 2026 earnings release is central here, because PROCEPT disclosed that handpiece sales had exceeded procedures every quarter since early 2023 and that excess field inventory had climbed above 10,000 units. Those disclosures, along with a sharp sequential drop in U.S. handpiece sales, are now at the core of the lawsuits and may prompt investors to reframe how they think about future guidance, utilization metrics, and any upcoming HYDROS placement updates.

Yet, against this backdrop, investors should also be aware that the lawsuits raise fresh questions about how sustainable handpiece demand really is and whether...

PROCEPT BioRobotics' narrative projects $608.2 million revenue and $77.8 million earnings by 2029. This requires 23.6% yearly revenue growth and a $180.3 million earnings increase from -$102.5 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value, a 70% upside to its current price.

Exploring Other Perspectives

Before this controversy, the most cautious analysts were already assuming about US$607,000,000 of revenue and US$74,000,000 of earnings by 2029, so if you worry that high operating costs and leadership turnover could slow adoption, their more pessimistic view shows just how far expectations can diverge and why it may be worth comparing several scenarios side by side.

Explore 7 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth just $20.24!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.